PCR Journal Club

Instent restenosis remains the Achilles heel of PCI. Drug eluting balloons offer a potential strategy for the treatment of instent restenosis. To date implantation of a further drug eluting stent provide better long term outcomes compared to paclitaxel drug eluting balloons. In this trial the authors...

In patients with non-left main coronary bifurcation lesions treated with provisional stenting and POT, the KISS randomised trial compares a strategy of no side branch intervention versus systematic side branch treatment.

In patients with moderate-to-severe calcified coronary lesions, ICARE OFDI evaluates IVL versus rotational atherectomy as lesion preparation strategies, with OFDI-based assessment of stent results.

The study aimed to evaluate the impact of LAAC device implantation depth on local flow characteristics and its association with device-related thrombus using patient-specific computational fluid dynamics.

Long-term evidence comparing PCI and CABG for unprotected left main coronary disease has been limited and sometimes conflicting. The 10-year results from the NOBLE trial now provide important clarity on all-cause mortality outcomes with both revascularisation strategies.

The RENOVATE-COMPLEX-PCI 5-year outcomes confirm the long-term durability of benefits seen with intracoronary imaging over angiography guided PCI in complex lesions.

Women have long been underrepresented in TAVR trials. This article explores the DEDICATE trial’s sex-specific outcomes after TAVI and SAVR, revealing differences in early stroke risk, procedural challenges, and one-year survival in men and women with aortic stenosis.

Catheter-based left atrial appendage closure (LAAC) is widely used as an alternative to oral anticoagulation in atrial fibrillation. But how does it compare with best medical therapy in patients at high risk of both stroke and bleeding? The CLOSURE-AF trial provides new data to inform this...

The ROLLING STONE registry compares intravascular lithotripsy (IVL) and atherectomy (rotational and orbital) for treating heavily calcified coronary arteries, assessing real-world safety and effectiveness in percutaneous coronary interventions (PCI).

This study provides the longest available follow-up for first-generation bioresorbable vascular scaffolds and fails to demonstrate any late clinical advantage after complete scaffold resorption.